Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type

Listen to Dr. Robert Coleman (USA) and Dr. Floor Backes (USA) discuss a new trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042. Video available at IGCS Education360 Learning Portal - https://edu360.igcs.org/URL/AU_05152024